GlassScriptPhysician profile
Raymond Bishop
NPI 1609865591
$2,607.13
in general payments reported to CMS, 2019-2025
18 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $404 · 2021: $473 · 2022: $441 · 2023: $95.26 · 2024: $544 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,072.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $437.05 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $246.35 | 2021-2025 | |
| Pfizer INC. | $244.19 | 2019-2025 | |
| Organon LLC | $113.85 | 2022 | |
| Novo Nordisk INC | $101.12 | 2019-2024 | |
| Amgen INC. | $59.31 | 2023-2025 | Repatha, Otezla, Repatha |
| Davol INC. | $49.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $42.35 | 2019 | |
| Abbott Laboratories | $41.57 | 2021-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $38.09 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.72 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $33.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.32 | 2024-2025 | Jardiance |
| Dexcom, INC. | $23.11 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.10 | 2019 | |
| Allergan, INC. | $13.58 | 2020 | |
| Amarin Pharma, INC. | $11.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.